Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Chicago Forest Laboratories |
---|---|
Information provided by: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00829296 |
The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
Condition | Intervention | Phase |
---|---|---|
Stiffness of the Arteries |
Drug: nebivolol |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Subject), Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | The Effects of Nebivolol on Aortic Impendance Parameters in Type 2 Diabetics |
Estimated Enrollment: | 60 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
nebivolol: Experimental
bystolic
|
Drug: nebivolol
taken once daily
|
To determine the effect of nebivolol versus metoprolol in Type 2 hypertensive diabetic patients on systolic blood pressure and diastolic blood pressure.
Ages Eligible for Study: | 50 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 | |
University of Chicago | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | George Bakris, M.D. | University of Chicago |
Responsible Party: | University of Chicago ( George Bakris, M.D. Principal Investigator ) |
Study ID Numbers: | 16310B (EFFORT trial) |
Study First Received: | January 26, 2009 |
Last Updated: | January 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00829296 History of Changes |
Health Authority: | United States: Institutional Review Board |
reducing stiffness of the arteries |
Neurotransmitter Agents Vasodilator Agents Heart Failure Adrenergic Agents Adrenergic beta-Antagonists |
Nebivolol Adrenergic Antagonists Cardiovascular Agents Antihypertensive Agents |
Neurotransmitter Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs |
Adrenergic beta-Antagonists Nebivolol Adrenergic Antagonists Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |